Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026)

Sunshine Biopharma filings provide 10 years of Return on Capital Employed readings, the most recent being 25.58% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 157.0% to 25.58% in Q4 2025 year-over-year; TTM through Dec 2025 was 25.58%, a 157.0% decrease, with the full-year FY2025 number at 26.08%, down 41.0% from a year prior.
  • Return on Capital Employed hit 25.58% in Q4 2025 for Sunshine Biopharma, up from 25.82% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 9.57% in Q3 2022 to a low of 309.07% in Q1 2021.
  • Median Return on Capital Employed over the past 5 years was 25.9% (2025), compared with a mean of 72.83%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -38965bps in 2021 and later soared 27810bps in 2022.
  • Sunshine Biopharma's Return on Capital Employed stood at 107.91% in 2021, then grew by 11bps to 96.01% in 2022, then skyrocketed by 77bps to 21.91% in 2023, then fell by -10bps to 24.02% in 2024, then decreased by -7bps to 25.58% in 2025.
  • The last three reported values for Return on Capital Employed were 25.58% (Q4 2025), 25.82% (Q3 2025), and 25.98% (Q2 2025) per Business Quant data.